Compare ARK Genomic Revolution ETF (ARKG) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs NEOS S&P 500 High Income ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.68, while NEOS S&P 500 High Income ETF trades at $53.6. Which is the better fit depends on your goals.
| ARKG | SPYI | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $43.57 | $54.07 |
52-Week Low | $23.09 | $47.98 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
SPYI trades at $53.70, up 0.36% on the day, with a bullish technical signal driven by moving averages and strong support at $53. The ETF has grown to over $10 billion in assets, highlighted by consistent monthly dividends and a yield near 12%. Recent news emphasizes its appeal for income-focused investors seeking S&P 500 exposure with reduced volatility.
Outlook remains positive due to robust investor inflows and a covered-call strategy that balances income with upside participation. Key risks include fee erosion over time and market sensitivity, but SPYI's diversification and high yield position it as a core holding for retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
